Research Keyword: drug-resistant fungi

Clinical Mycology Today: Emerging Challenges and Opportunities

mycolabadmin

Fungal infections are becoming more common because of new medical treatments that suppress immune function, and some fungi are developing resistance to standard medications. However, exciting new antifungal drugs are in development that work in different ways and may be easier to use. The article discusses how doctors need better ways to identify patients at risk, design better clinical trials, and train more specialists to handle these increasingly complex fungal infections.

Read More »

Healthcare-associated fungal infections and emerging pathogens during the COVID-19 pandemic

mycolabadmin

During the COVID-19 pandemic, fungal infections became a serious complication in hospitalized patients, especially those receiving steroids and other immune-suppressing treatments. Common fungal pathogens like Candida and Aspergillus caused dangerous coinfections, with infection rates varying significantly by region. Current antifungal medications have significant limitations including toxicity and resistance, highlighting the urgent need for new and safer antifungal treatments.

Read More »

Emergence of resistant dermatophytosis caused by Trichophyton indotineae: First case series in Thailand

mycolabadmin

Doctors in Thailand have identified a new drug-resistant fungal infection caused by Trichophyton indotineae, a fungus that doesn’t respond to common antifungal medication terbinafine. Five patients were diagnosed with this resistant skin infection that caused rashes on various body parts and failed to improve with standard treatments. The research shows that a simple urease test can help doctors quickly identify this resistant fungus, and a different drug called itraconazole appears to work better for treatment. This is the first time this resistant fungus has been confirmed in Thailand, suggesting it is spreading globally.

Read More »

Clinical Mycology Today: Emerging Challenges and Opportunities

mycolabadmin

Fungal infections are becoming more common due to new cancer treatments and other medical advances, while some fungal species are developing resistance to standard antifungal medications. The good news is that several new antifungal drugs are in development with better safety profiles and novel mechanisms to fight these infections. However, the field faces challenges including limited specialized mycologists and difficulty designing clinical trials to properly test new treatments.

Read More »

A broad-spectrum anti-fungal effector dictates bacterial-fungal interkingdom interactions

mycolabadmin

Scientists discovered that a common soil bacterium called Acidovorax citrulli has a sophisticated weapon to fight dangerous fungi. This bacterium uses a needle-like structure to inject a toxic protein called TseN directly into fungal cells, where it damages the fungal DNA and causes death. This new discovery is particularly exciting because it works against drug-resistant fungi like Candida auris that are increasingly hard to treat. Tests in mice confirmed that this bacterial attack significantly reduces fungal infections on skin.

Read More »

Exploring the Antifungal Potential of Lawsone-Loaded Mesoporous Silica Nanoparticles Against Candida albicans and Candida glabrata: Growth Inhibition and Biofilm Disruption

mycolabadmin

Researchers developed a new antifungal treatment by loading lawsone (a compound from henna plants) into tiny particles called mesoporous silica nanoparticles. When tested against common fungal infections caused by Candida bacteria, this nano-formulation was more effective than lawsone alone at killing the fungi and breaking down protective biofilm structures. The treatment showed no harm to normal human cells, suggesting it could be a promising natural alternative to treat stubborn fungal infections that resist current antifungal drugs.

Read More »

Insights into the structure, function, and impact of Candida albicans UPC2 gene on azole resistance; a mini-review

mycolabadmin

Candida albicans is a common fungal infection that doctors treat with azole medications, but the fungus is increasingly developing resistance to these drugs. Scientists have discovered that a gene called UPC2 plays a key role in this resistance by controlling the production of enzymes that help the fungus survive azole treatment. Understanding how UPC2 works could help develop new strategies to overcome drug-resistant fungal infections.

Read More »
Scroll to Top